-
1.发明申请COMBINATION OF BLyS INHIBITION AND ANTI-CD 20 AGENTS FOR TREATMENT OF AUTOIMMUNE DISEASE 有权用于治疗自身免疫疾病的BLYS抑制剂和抗CD 20剂的组合公开(公告)号：US20090148442A1
公开(公告)日：2009-06-11
申请号：US12252955
申请日：2008-10-16
IPC分类号： A61K39/395 , A61K38/16 , A61P37/02
CPC分类号： A61K39/3955 , A61K38/1709 , A61K38/1793 , A61K39/395 , A61K39/39541 , A61K45/06 , A61K2300/00
摘要： The invention relates to novel combination therapies involving BLyS or BLyS/APRIL inhibition and anti-CD20 agents for the treatment of autoimmune diseases. One preferred method is where the BLyS antagonist is a Fc-fusion protein which can be a TACI-Fc-fusion protein comprising the extracellular domain of TACI or a functional fragment thereof, a BAFF—R-Fc-fusion protein comprising the extracellular domain of BAFF—R or a functional fragment thereof, or a BCMA-Fc-fusion protein comprising the extracellular domain of BCMA or a functional fragment thereof. In the methods of the present invention some of anti-CD20 agents contemplated include RITUXAN®, ocrelizumab, ofatumumab (HuMax-CD20®), TRU-015, and DXL625, although any agent that binds to CD 20 may be suitable. The methods of the present invention reduce the levels of B cells in patients in need of such reduction, such as those suffering from autoimmune diseases.
摘要翻译： 本发明涉及涉及BLyS或BLyS / APRIL抑制的新型联合疗法和用于治疗自身免疫性疾病的抗CD20剂。 一种优选的方法是其中BLyS拮抗剂是Fc-融合蛋白，其可以是包含TACI的胞外结构域或其功能片段的TACI-Fc-融合蛋白，包含细胞外结构域的BAFF-R-Fc-融合蛋白 BAFF-R或其功能片段，或包含BCMA细胞外结构域的BCMA-Fc-融合蛋白或其功能片段。 在本发明的方法中，考虑的一些抗CD20药物包括RITUXAN，ocrelizumab，奥美单抗（HuMax-CD20），TRU-015和DXL625，尽管与CD20结合的任何试剂可能是合适的 。 本发明的方法降低了需要这种还原的患者中的B细胞的水平，例如患有自身免疫性疾病的患者。
-
2.发明授权Combination of BLyS inhibition and anti-CD 20 agents for treatment of autoimmune disease 有权BLyS抑制和抗CD 20药物联合用于治疗自身免疫性疾病公开(公告)号：US08956611B2
公开(公告)日：2015-02-17
申请号：US12252955
申请日：2008-10-16
IPC分类号： A61K39/395 , A61K45/06 , A61K38/17
CPC分类号： A61K39/3955 , A61K38/1709 , A61K38/1793 , A61K39/395 , A61K39/39541 , A61K45/06 , A61K2300/00
摘要： The invention relates to novel combination therapies involving BLyS or BLyS/APRIL inhibition and anti-CD20 agents for the treatment of autoimmune diseases. One preferred method is where the BLyS antagonist is a Fc-fusion protein which can be a TACI-Fc-fusion protein comprising the extracellular domain of TACI or a functional fragment thereof, a BAFF—R-Fc-fusion protein comprising the extracellular domain of BAFF—R or a functional fragment thereof, or a BCMA-Fc-fusion protein comprising the extracellular domain of BCMA or a functional fragment thereof. In the methods of the present invention some of anti-CD20 agents contemplated include RITUXAN®, (rituximab),ocrelizumab, ofatumumab (HuMax-CD20®), TRU-015, and DXL625, although any agent that binds to CD 20 may be suitable. The methods of the present invention reduce the levels of B cells in patients in need of such reduction, such as those suffering from autoimmune diseases.
摘要翻译： 本发明涉及涉及BLyS或BLyS / APRIL抑制的新型联合疗法和用于治疗自身免疫性疾病的抗CD20剂。 一种优选的方法是其中BLyS拮抗剂是Fc-融合蛋白，其可以是包含TACI的胞外结构域或其功能片段的TACI-Fc-融合蛋白，包含细胞外结构域的BAFF-R-Fc-融合蛋白 BAFF-R或其功能片段，或包含BCMA细胞外结构域的BCMA-Fc-融合蛋白或其功能片段。 在本发明的方法中，考虑的一些抗CD20药物包括RITUXAN，（利妥昔单抗），ocrelizumab，奥美珠单抗（HuMax-CD20），TRU-015和DXL625，尽管与CD20结合的任何试剂可能是合适的 。 本发明的方法降低了需要这种还原的患者中的B细胞的水平，例如患有自身免疫性疾病的患者。
-
3.发明授权Combination of BLyS and/or APRIL inhibition and immunosuppressants for treatment of autoimmune disease 有权BLyS和/或APRIL抑制剂的组合以及用于治疗自身免疫性疾病的免疫抑制剂公开(公告)号：US08852591B2
公开(公告)日：2014-10-07
申请号：US12057133
申请日：2008-03-27
申请人： Rafael A. Ponce, Jr. , Wayne J. Wallis , Matthew S. Holdren , Linda Zuckerman , Alisa M. Littau , Kirk P. Van Ness , Claudia Pena Rossi , Hans Otto Lennart Graffner
发明人： Rafael A. Ponce, Jr. , Wayne J. Wallis , Matthew S. Holdren , Linda Zuckerman , Alisa M. Littau , Kirk P. Van Ness , Claudia Pena Rossi , Hans Otto Lennart Graffner
IPC分类号： A61K39/395 , A61K38/17 , A61K45/06
CPC分类号： A61K39/3955 , A61K31/5377 , A61K38/1793 , A61K45/06 , A61K2300/00
摘要： The invention relates to novel combination therapies involving BLyS or BLyS/APRIL inhibition and immunosuppressants for the treatment of autoimmune diseases. One preferred method is where the BLyS and/or APRIL antagonist is a Fc-fusion protein which can be a TACI-Fc-fusion protein comprising the extracellular domain of TACI or a functional fragment thereof, a BAFF-R-Fc-fusion protein comprising the extracellular domain of BAFF-R or a functional fragment thereof, or a BCMA-Fc-fusion protein comprising the extracellular domain of BCMA or a functional fragment thereof. In the methods of the present invention some of the immunosuppressive drugs contemplated include cyclophosphamide (CYC), azathioprine (AZA), cyclosporine A (CSA), or mycophenolate mofetil (MMF), although any drug that suppresses the immune system may be suitable. The methods of the present invention reduce the levels of various immunoglobulins in patients in need of such reduction, such as those suffering from autoimmune diseases.
摘要翻译： 本发明涉及涉及BLyS或BLyS / APRIL抑制的新型联合疗法和用于治疗自身免疫性疾病的免疫抑制剂。 一个优选的方法是其中BLyS和/或APRIL拮抗剂是Fc-融合蛋白，其可以是包含TACI的细胞外结构域或其功能片段的TACI-Fc-融合蛋白，包含BAFF-R-Fc-融合蛋白的BAFF-R-Fc-融合蛋白 BAFF-R的细胞外结构域或其功能片段，或包含BCMA细胞外结构域或其功能片段的BCMA-Fc-融合蛋白。 在本发明的方法中，考虑到一些免疫抑制药物包括环磷酰胺（CYC），硫唑嘌呤（AZA），环孢菌素A（CSA）或霉酚酸酯（MMF），尽管抑制免疫系统的任何药物都是合适的。 本发明的方法降低了需要这种还原的患者中各种免疫球蛋白的水平，如患有自身免疫性疾病的患者。
-
4.发明申请COMBINATION OF BLyS AND/OR APRIL INHIBITION AND IMMUNNOSUPPRESSANTS FOR TREATMENT OF AUTOIMMUNE DISEASE 有权BLYS和/或APRIL抑制剂的组合和免疫抑制剂治疗自发性疾病公开(公告)号：US20080260737A1
公开(公告)日：2008-10-23
申请号：US12057133
申请日：2008-03-27
申请人： Rafael A. Ponce , Wayne J. Wallis , Matthew S. Holdren , Linda Zuckerman , Alisa M. Littau , Kirk P. Van Ness , Claudia Pena Rossi , Hans Otto Lennart Graffner
发明人： Rafael A. Ponce , Wayne J. Wallis , Matthew S. Holdren , Linda Zuckerman , Alisa M. Littau , Kirk P. Van Ness , Claudia Pena Rossi , Hans Otto Lennart Graffner
IPC分类号： A61K39/395 , A61P37/00
CPC分类号： A61K39/3955 , A61K31/5377 , A61K38/1793 , A61K45/06 , A61K2300/00
摘要： The invention relates to novel combination therapies involving BLyS or BLyS/APRIL inhibition and immunosuppressants for the treatment of autoimmune diseases. One preferred method is where the BLyS and/or APRIL antagonist is a Fc-fusion protein which can be a TACI-Fc-fusion protein comprising the extracellular domain of TACI or a functional fragment thereof, a BAFF-R-Fc-fusion protein comprising the extracellular domain of BAFF-R or a functional fragment thereof, or a BCMA-Fc-fusion protein comprising the extracellular domain of BCMA or a functional fragment thereof. In the methods of the present invention some of the immunosuppressive drugs contemplated include cyclophosphamide (CYC), azathioprine (AZA), cyclosporine A (CSA), or mycophenolate mofetil (MMF), although any drug that suppresses the immune system may be suitable. The methods of the present invention reduce the levels of various immunoglobulins in patients in need of such reduction, such as those suffering from autoimmune diseases.
摘要翻译： 本发明涉及涉及BLyS或BLyS / APRIL抑制的新型联合疗法和用于治疗自身免疫性疾病的免疫抑制剂。 一个优选的方法是其中BLyS和/或APRIL拮抗剂是Fc-融合蛋白，其可以是包含TACI的细胞外结构域或其功能片段的TACI-Fc-融合蛋白，包含BAFF-R-Fc-融合蛋白的BAFF-R-Fc-融合蛋白 BAFF-R的细胞外结构域或其功能片段，或包含BCMA细胞外结构域或其功能片段的BCMA-Fc-融合蛋白。 在本发明的方法中，考虑到一些免疫抑制药物包括环磷酰胺（CYC），硫唑嘌呤（AZA），环孢菌素A（CSA）或霉酚酸酯（MMF），尽管抑制免疫系统的任何药物都是合适的。 本发明的方法降低了需要这种还原的患者中各种免疫球蛋白的水平，如患有自身免疫性疾病的患者。
-
-
-
搜索结果
4 条记录 (耗时 0.032 秒)
